Investigating the barriers to bioavailability of macrolide antibiotics in the rat

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 3, 2012, Pages 163-171

  Padovan, Jasna ^a   Ralić, Jovica ^a   Letfus, Vatroslav ^a   Milić, Astrid ^a   Mihaljevic, Vlatka Bencetić ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Barriers; Bioavailability; Macrolide antibiotics; Pharmacokinetics; Rat

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN; TELITHROMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CLARITHROMYCIN; ERYTHROMYCIN; HEPATOCYTES; KETOLIDES; MACROLIDES; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; ROXITHROMYCIN;

EID: 84871278726     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0074-5     Document Type: Article

References (20)

1. Albarellos GS, Kreil VE, Ambros LA, Waxman S, Montoya L, Tarragona L, Quaine PC, Hallu RE, Rebuelto M (2008) Pharmacokinetics of erythromycin after the administration of intravenous and various oral dosage forms to dogs. J Vet Pharmacol Ther 31:496-500
2. Berry MN, Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells. A biochemical and fine structural study. J Cell Biol 43:506-520
3. Bryskier A (1998) Roxithromycin: review of its antimicrobial activity. J Antimicrob Chemother 41:1-21
4. Chaturvedi PR, Deckerl CJ, Odinecs A (2001) Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Biol 5:452-463
5. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095
6. Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ (2007) Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 81:828-832
7. Garver E, Hugger ED, Shearn SP, Rao A, Dawson PA, Davis CB, Han C (2008) Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat. Drug Metab Dispos 36:2492-2498
8. Jain R, Danziger LH (2004) The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Res 10:3045-3053
9. Kirst HA, Sides GD (1989) New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 33:1419-1422
10. Kohno Y, Yoshida H, Suwa T, Suga T (1989) Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotics, and erythromycin in rats. Antimicrob Agents Chemother 33:751-756
11. Kwon Y (2001) Handbook of essential pharmacokinetics. Pharmacodynamics and drug metabolism for industrial scientists. Kluwer Academic/Plenum Publishers, New York, pp 47-53
12. Lee JH, Lee MG (2007) Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability. J Pharm Pharmaceut Sci 10:37-50
13. Munić V, Kelnerić Z, Mikac L, Eraković Haber V (2010) Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci 41:86-95
14. Nozinic D, Milic A, Mikac L, Ralic J, Padovan J, Antolović R (2010) Assessment of macrolide transport using PAMPA, Caco-2 and MDCKII-hMDR1 assays. Croat Chem Acta 83:323-331
15. Pachot JI, Botham RP, Haegele KD, Hwang K (2003) Experimental estimation of the role of P-glycoprotein in the pharmacokinetic behavior of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci 6:1-12
16. Somogyi AA, Bochner F, Hetzel D, Williams DB (1995) Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin. Pharm Res 12:149-154
17. Sood SK (1999) Macrolides: clarithromycin and azithromycin. Semin Pedatr Infect Dis 10:23-30
18. Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, Kitaichi K, Takagi K, Takagi K, Hasegawa T (2004) Possible involvement of the drug transporters P-glycoprotein and multi-drug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 48:809-814
19. Tabata K, Yamaoka K, Fukuyama T, Nakagawa T (1995) Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm Res 12:880-883
20. Zuckerman JM, Qamar F, Bono BR (2009) Macrolides, ketolides and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infec Dis Clin N Am 23:997-1026